Calidi Biotherapeutics
CLDI
22 hedge funds and large institutions have $89.3K invested in Calidi Biotherapeutics in 2026 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 7 increasing their positions, 0 reducing their positions, and 9 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
1.53% less ownership
Funds ownership: 1.7% → 0.17% (-1.5%)
19% less funds holding
Funds holding: 27 → 22 (-5)
56% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 9
81% less capital invested
Capital invested by funds: $479K → $89.3K (-$389K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Geode Capital Management
Boston,
Massachusetts
|
+$10.4K |
| 2 |
IAA
Independent Advisor Alliance
Charlotte,
North Carolina
|
+$9.09K |
| 3 |
PAG
Private Advisor Group
Morristown,
New Jersey
|
+$6.06K |
| 4 |
Jane Street
New York
|
+$3.93K |
| 5 |
RA
RFG Advisory
Birmingham,
Alabama
|
+$2.42K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
-$210K |
| 2 |
SM
Sabby Management
Miami Beach,
Florida
|
-$104K |
| 3 |
WAM
Warberg Asset Management
Winnetka,
Illinois
|
-$59.5K |
| 4 |
VF
Virtu Financial
New York
|
-$18K |
| 5 |
Vanguard Fiduciary Trust
Malvern,
Pennsylvania
|
-$2.2K |
CLDI Hedge Fund Activity: Q2 2026 in Review
22 of the 8,316 institutional investors tracked by Wall St. Rank reported a position in Calidi Biotherapeutics (CLDI) for Q2 2026, worth a combined $89.3K — down 81% from $479K a quarter earlier.
Sellers outnumbered buyers: 9 funds closed out of CLDI and 4 opened new positions — a net loss of 5 holders — while 0 trimmed existing stakes and 7 added.
The largest buyer was Geode Capital Management, adding an estimated $10.4K. The largest seller was Armistice Capital, exiting entirely with an estimated $210K sold.
- 22 institutional investors held Calidi Biotherapeutics (CLDI) as of Q2 2026, down from 27 in Q1 2026.
- Funds reported $89.3K of Calidi Biotherapeutics stock for Q2 2026, down 81% quarter-over-quarter.
- 4 funds opened new Calidi Biotherapeutics positions in Q2 2026 and 9 closed out, a net change of -5 holders.
- The largest Calidi Biotherapeutics buyer in Q2 2026 was Geode Capital Management, an estimated $10.4K added.
- The largest Calidi Biotherapeutics seller in Q2 2026 was Armistice Capital, an estimated $210K sold.
Based on aggregated 13F filings for Q2 2026.